The European Medicines Agency (EMA) has launched an initiative that offers free-of-charge, early paediatric interaction meetings with medicines developers to stimulate early dialogue on the development of their medicines for use in children. A one-year pilot phase has started as of June 2015.
The new initiative aims to encourage discussions on the paediatric needs that could be addressed with a specific medicine well before the submission of a paediatric investigation plan (PIP). Medicines developers who wish to participate in the pilot phase are invited to provide information on their medicine and send it on to paediatrics@ema.europa.eu.